NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.50 · Revenue $7.54M · 8 analysts
Est. EPS $-0.46 · Revenue $15.79M · 9 analysts
Est. EPS $-1.89 · Revenue $30.26M · 10 analysts
Est. EPS $-0.59 · Revenue $1.62M · 6 analysts
EPS $-0.34 · Revenue $2.98M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $22.5M | -50.6% | +21.7% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-203.8M | +15.6% | -32.4% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +99.7% | -0.3% | +19.7% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -1002.9% | -159.2% | +8.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -905.7% | -70.8% | -8.8% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-148.0M | +7.0% | -28.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -657.8% | -88.2% | -5.3% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.0% | -50.0% | +275.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 7.88x | -2.5% | -7.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $769.3M | -11.0% | -3.8% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.75 vs -1.54 | -13.8% | -0.52 vs -0.50 | -5.0% |
| Revenue Surprise | $22.5M vs $27.0M | -16.6% | $3.7M vs $7.5M | -50.9% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 24, 2026 | Kastelein Johannes Jacob Pieter | director, officer: Chief Scientific Officer | Option (right to buy) | D | 125,000 | — |
| Aug 24, 2026 | Kastelein Johannes Jacob Pieter | director, officer: Chief Scientific Officer | Ordinary Shares | A | 125,000 | — |
| Aug 24, 2026 | Kastelein Johannes Jacob Pieter | director, officer: Chief Scientific Officer | Ordinary Shares | D | 125,000 | $26.91 |
| Aug 10, 2026 | Gunning Robert William | — | — | — | 0 | — |
| Jul 20, 2026 | Kooij Louise Frederika | officer: Chief Accounting Officer | Ordinary Shares | A | 80,000 | $11.17 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Michael Harvey Davidson FACC Facp. | CEO, President & Executive Director | USD 1,139,142 | — | 1956 | Active |
Johannes Jacob Pieter Kastelein FESC | Founder, Chief Scientific Officer, Member of Executive Board & Director | USD 808,143 | — | 1954 | Active |
Douglas F. Kling | Chief Operating Officer | USD 790,051 | Male | 1973 | Active |
Mayur Amrat Somaiya | Chief Financial Officer | USD 770,393 | Male | 1974 | Active |
Louise Kooij | Chief Accounting Officer | USD 695,419 | Female | 1976 | Active |
Juliette Audet | Chief Strategy & Business Officer | USD 653,039 | Female | 1987 | Active |
Marc Ditmarsch | Chief Development Officer | — | — | 1967 | Active |
Chris Deluzio | Executive Vice President of Sales Enterprise Operations | — | Male | — | Active |
Michael F. Marino | Chief Legal Officer & Corporate Secretary | — | Male | 1976 | Active |
Maryellen McQuade | Chief People Officer | — | Female | — | Active |
Matthew Philippe | Executive VP & Head of Investor Relations | — | Male | — | Active |
Handelsbanken Fonder AB lessened its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 70.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 122,400 shares of the company's stock after selling 296,500 shares during the quarter. Handelsbanken Fonder AB owned 0.10%
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript
NewAmsterdam Pharma NASDAQ: NAMS used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch.
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48.
– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from RUBENS Phase 3 expected by year-end 2026 – – $678.3 million in cash, cash equivalents and marketable securities at June 30, 2026 – – Company to host investor day today at 9:00 AM ET in New York City – NAARDEN, the Netherlands and MIAMI, Aug. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the quarter ended June 30, 2026 and provided a corporate update.
